^
Association details:
| Biomarker: | TP53 wild-type + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) + Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer
Published date:
04/05/2022
Excerpt:
Results showed that both tucidinostat and selinexor showed better inhibitory activities on wt-TP53 BC (MCF-7 and MDA-MB-175) comparing with mut-TP53 BC (MDA-MB-134 and T47D). Tucidinostat combined with selinexor significantly improved the effects of tucidinostat alone on the proliferation and invasion inhibitions and apoptosis promotions of MCF-7 and MDA-MB-175 cells in vitro.
DOI:
10.1016/j.mce.2022.111558
